This suggests a possible upside of 119.3% from the stock's current price. How has Citius Pharmaceuticals's share price performed over time and what events caused price changes? The Company is focused on developing and commercializing care products with a focus on anti-infective products in adjunct cancer care and prescription products. Industry Biotechnology More. 1st floor. Citius Pharmaceuticals Inc. (CTXR) full year performance was 198.88% Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. Citius has 9 employees and is ranked 14th among it's top 10 competitors. Cranford, NJ 07016 ... Non-employee directors each receive an annual retainer of $32,500, but no compensation for meetings attended. Our products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market positioning. Employees at Citius Pharmaceuticals, Inc. Myron Holubiak Chief Executive Officer at Citius Pharmaceuticals, Inc. (formerly Leonard Meron Biosciences, Inc.) Jobs At Similar Companies Customer Technology Manager - Bio-Reference Laboratories Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve leading market position or market exclusivity. Phone 1 908 967-6677. Citius Pharmaceuticals, Inc. Ticker CTXR. May 13, 2021 - 7:30 am. How many employees are working in Citius Pharmaceuticals? Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677. Sec Filling | Patents | 9 employees Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius Pharmaceuticals has 9 employees "The Citius team is focused on advancing a growing pipeline of first-in-class treatment options that have the potential to … Approved by the Stockholders: February 7, 2018 . Understanding current and past Citius Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. 2 brokers have issued 1-year target prices for Citius Pharmaceuticals' stock. (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934. See insights on Citius Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Citius President and CEO, Myron Holubiak, was featured in an … CRANFORD, N.J., Feb. 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critic... 3 months ago - PRNewsWire. Industry Pharmaceuticals. The company is engaged in the development and commercialization of anti … A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Learn more about the sector, industry, classification, employee size, and executives of … Citius Pharmaceuticals has 9 employees at their 1 location and $90 K in annual revenue in FY 2020. Citius Pharmaceuticals Invested Capital is relatively stable at the moment as compared to the past year. Washington, D.C. 20549. Citius Pharmaceuticals, Inc. (Form: 10-Q, Received: 02/14/2019 17:47:55) U.S. SECURITIES AND EXCHANGE COMMISSION. See the company profile and updated insider trades of CITIUS PHARMACEUTICALS, INC. (CTXR). Citius Pharmaceuticals number of employees from 2013 to 2020. Citius Pharmaceuticals Inc. 11 Commerce Drive. Prior to joining Citius, Dr. Lader was the Director of Clinical Operations for Ischemix, Inc. Dr. Lader was an Instructor in Medicine at Harvard Medical School and Brigham and Women’s Hospital, where he taught Integrated Human Physiology, and was Principal Investigator for NIH-funded studies in mechanisms of lung cancer metastasis. Dr. 10. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on … Citius Pharmaceuticals Inc is a specialty pharmaceutical company. Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Company profile page for Citius Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. About Citius Pharmaceuticals, Inc. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com. The company executives may have good odds in positioning the firm resources to exploit market volatility in July.The stock standard deviation of daily returns for 90 days investing horizon is currently 4.62. CRANFORD, N.J., April 22, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that Citius President and … For the quarterly period ended: December 31, 2018. Cranford, New Jersey 07016. Citius Pharmaceuticals (CTXR) Given Exclusive COVID-19 Stem-Cell License. Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. The top 10 competitors average 160. The 1-year high price for the company’s stock is recorded $2.90 on 02/22/21, with the lowest value was $1.00 for the same time period, recorded on 01/04/21. February 17, 2021 - 12:28 am. ... OF EMPLOYEES. Citius Pharmaceuticals is the mind behind Mini-Lok, a patented solution to treat catheter infections. Citius Pharmaceuticals Inc is a specialty pharmaceutical company. Reflecting on the efficiency of the workforce at the company, Citius Pharmaceuticals Inc. [CTXR] managed to generate an average of -$1,754,808 per employee.Citius Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 35.20 and a … Do NOT follow this link! Citius Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. CRANFORD, N.J., May 13, 2021-- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today reported financial results for the second fiscal quarter of 2021 and provided a general business update. 1-10 Employees. Citius Pharmaceuticals, Inc. (“Company”) has successfully traversed 2020 following what was a challenging year for so many. Sector Healthcare More. LMB was a pharmaceutical company focused on the development and commercialization of critical care products with a concentration on anti-infectives. Citius Pharmaceuticals, LLC became a wholly-owned subsidiary of Citius. They focus on the development of therapeutic and critical care devices. OR. Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius products offer new and expanded indications for previously approved pharmaceutical … Their forecasts range from $4.00 to $6.00. See the company profile for Citius Pharmaceuticals, Inc. (CTXR) including business summary, industry/sector information, number of employees, business summary, corporate governance, key … Chairman of the Board. Based in Cranford, New Jersey. On average, they anticipate Citius Pharmaceuticals' share price to reach $5.00 in the next year. Reflecting on the efficiency of the workforce at the company, Citius Pharmaceuticals Inc. [CTXR] managed to generate an average of -$1,754,808 per employee.Citius Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.60. Leonard Mazur. Citius Pharmaceuticals is a specialty pharmaceutical company that you most likely have never heard of. Approved by the Board: December 12, 2017. CorMedix is Citius's #1 competitor. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Citius Pharmaceuticals against related stocks people have also bought like AGTC, SENS, ZOM, and ASRT. Sector … Citius’ Leadership Team includes senior pharmaceutical company executives having sustained track records of accomplishment in advancing clinical assets and commercialization of pharmaceutical products, as well as experience in building shareholder value. Julia has 7 jobs listed on their profile. Citius Pharmaceuticals CEO Myron Holubiak Featured in Benzinga Interview. Mr. Mazur is an accomplished entrepreneur and pharmaceutical industry executive with notable … The latest price spike of Citius Pharmaceuticals could raise concerns from retail investors as the firm it trading at a share price of 2.32 on 4,772,122 in volume. 1. Citius Pharmaceuticals, Inc. 11 Commerce Drive, 1st Floor. Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. FORM 10-Q. About Citius Pharmaceuticals, Inc. Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) posted its quarterly earnings results on Wednesday, February, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by $0.31. CRANFORD, N.J., Feb. 17, 2021-- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for … View the real-time CTXR price chart on Robinhood and decide if you want to buy or sell commission-free. Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules. Latest Share Price and Events Stable Share Price : CTXR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week. Together they have raised over 2.4B between their estimated 2.3K employees. Citius is currently advancing two proprietary product candidates, Mino-Lok product and a Hydrocortisone-Lidocaine formulation. On March 30, 2016, Citius acquired Leonard-Meron Biosciences, Inc. (“LMB”) as a wholly-owned subsidiary. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. It has three product candidates: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Thankfully, all of our employees and their loved ones have been able to avoid COVID-19 infections as we implemented various measures to keep our employees and visitors safe and virus-free. Citius Pharmaceuticals Inc is a specialty pharmaceutical company. CITIUS PHARMACEUTICALS, INC. 2018 omnibus STOCK INCENTIVE PLAN . View Julia Carlino-Stiffler’s profile on LinkedIn, the world’s largest professional community. Purposes of the Plan. ☐ TRANSITION REPORT PURSUANT TO … Citius Pharmaceuticals reported last year Invested Capital of 1.36 Million. --Citius Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a … Exchange NASDAQ More. The company is engaged in the development and commercialization of anti-infective products, adjunctive cancer care, and unique prescription products. Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets.
Tennis Cool Down Games,
Cottage For Rent Shelburne, Ns,
Oublie-le French Pronunciation,
Gordon Hayward Anta Shirt,
Amish Restaurant Near Me,